Nutritional compositions containing a prebiotic and lactoferrin and uses thereof

Patent metadata

Field	Value
Publication number	US-10709770-B2
Application number	US-201514636810-A
Country	US
Kind code	B2
Filing date	Mar 3, 2015
Priority date	Jul 31, 2013
Publication date	Jul 14, 2020
Grant date	Jul 14, 2020

Abstract

Provided is a composition and method for modulating serotonergic receptor expression, reducing anxiety-like behavior and stress-induced inflammatory response in a pediatric subject, the method including administering to the pediatric subject a nutritional composition including lactoferrin from a non-human source and a prebiotic composition including polydextrose and/or galactooligosaccharides. Further provided is a method for reducing constipation in a pediatric subject by providing a nutritional composition including lactoferrin from a non-human source and a prebiotic composition including polydextrose and/or galactooligosaccharides.

First claim

What is claimed is:

1. A method for increasing serotonergic receptor expression in a pediatric subject, the method comprising administering to the pediatric subject a nutritional composition comprising:
up to about 7 g/100 kcal of a fat or lipid source, wherein the fat or lipid source comprises milk fat globules derived from an enriched lipid fraction of bovine milk, wherein the enriched lipid fraction comprises from about 0.2 g/100 kcal to about 5.82 g/100 kcal of branched chain fatty acids and from about 50 mg/100 kcal to about 200 mg/100 kcal of phospholipids;
between about 15 mg/100 kcal and about 300 mg/100 kcal of lactoferrin from a non-human source;
about 0.015 g/100 kcal to about 1.5 g/100 kcal of a prebiotic composition, wherein the prebiotic composition comprises polydextrose and a galacto-oligosaccharide;
a source of long chain polyunsaturated fatty acids; and
a preservative comprising potassium sorbate, sodium sorbate, potassium benzoate, sodium benzoate, calcium disodium EDTA, or a combination thereof, and
wherein upon administration of the nutritional composition, the pediatric subject experiences increased serotonergic receptor expression.

2. The method of claim 1 , wherein the source of long chain polyunsaturated fatty acids includes at least one of docosahexaenoic acid, arachidonic acid, and combinations thereof.

3. The method of claim 1 , wherein the source of long chain polyunsaturated fatty acids is present from about 5 mg/100 kcal to about 75 mg/100 kcal.

4. The method of claim 1 , wherein the milk fat globules further comprise gangliosides and phospholipids.

5. The method of claim 1 , wherein lactoferrin is present at a level of about 60 mg/100 kcal to about 200 mg/100 kcal.

6. The method of claim 5 , wherein the lactoferrin is bovine lactoferrin.

7. The method of claim 1 , wherein the nutritional composition further comprises a protein source.

8. The method of claim 1 , wherein polydextrose and galactooligosaccharides comprise at least about 20% of the prebiotic composition.

9. The method of claim 1 , wherein the nutritional composition is an infant formula or a growing up milk.

10. A nutritional composition for reducing constipation in a pediatric subject, comprising:
up to about 7 g/100 kcal of a fat or lipid source, wherein the fat or lipid source comprises milk fat globules derived from an enriched lipid fraction from bovine milk, wherein the enriched lipid fraction comprises from about 0.2 g/100 kcal to about 5.82 g/100 kcal of branched chain fatty acids and from about 50 mg/100 kcal to about 200 mg/100 kcal of phospholipids;
up to about 5 g/100 kcal of a protein source;
between about 15 mg/100 kcal and about 300 mg/100 kcal of lactoferrin from a non-human source;
about 0.015 g/100 kcal to about 1.5 g/100 kcal of a prebiotic composition, wherein the prebiotic composition comprises polydextrose and galactooligosaccharide;
a source of long chain polyunsaturated fatty acids comprising docosahexaenoic acid, arachidonic acid, and combinations thereof; and
a preservative comprising potassium sorbate, sodium sorbate, potassium benzoate, sodium benzoate, calcium disodium EDTA, or a combination thereof, and
wherein upon administration of the nutritional composition the pediatric subject experiences a reduction in constipation.

11. The composition of claim 10 , wherein the source of long chain polyunsaturated fatty acids is present from about 5 mg/100 kcal to about 75 mg/100 kcal.

12. The composition of claim 10 , wherein the average diameter of the milk fat globules range is at least about 2 μm.

13. The composition of claim 12 , wherein the average diameter of the milk fat globules range is in the range of about 2 μm to about 13 μm.

14. The composition of claim 10 , wherein the specific surface area of the milk fat globules range is in the range of about 0.9 m 2 /g to about 3 m 2 /g.

15. The composition of claim 10 , wherein the lactoferrin is bovine lactoferrin.

16. The composition of claim 10 , wherein polydextrose and galactooligosaccharides comprise at least about 20% of the prebiotic composition.

17. The composition of claim 10 , wherein the nutritional composition is an infant formula or a growing up milk.

18. The composition of claim 10 , wherein lactoferrin is present at a level of about 60 mg/100 kcal to about 200 mg/100 kcal.

Assignees

• Mead Johnson Nutrition Co

Inventors

• Chichlowski Maciej
• Berg Brian
• Jouni Zeina
• Wittke Anja
• Waworuntu Rosaline

Classifications

• A61K38/482 Primary

  Serine endopeptidases (3.4.21) · CPC title

• C12Y304/21

  Serine endopeptidases (3.4.21) · CPC title

• A61K31/702

  Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages · CPC title

• A61K38/40

  Transferrins, e.g. lactoferrins, ovotransferrins · CPC title

• A23L33/115

  Fatty acids or derivatives thereof; Fats or oils · CPC title